4//SEC Filing
Parrish Jay 4
Accession 0001209191-21-016880
CIK 0001706431other
Filed
Mar 2, 7:00 PM ET
Accepted
Mar 3, 4:35 PM ET
Size
12.7 KB
Accession
0001209191-21-016880
Insider Transaction Report
Form 4
Parrish Jay
Chief Business Officer
Transactions
- Exercise/Conversion
Common Stock
2021-03-01$1.49/sh+4,630$6,876→ 13,890 total - Exercise/Conversion
Common Stock
2021-03-01$1.57/sh+2,314$3,645→ 16,204 total - Sale
Common Stock
2021-03-01$63.44/sh−6,944$440,531→ 9,260 total - Exercise/Conversion
Stock Option (Right to Buy)
2021-03-01−4,630→ 9,259 totalExercise: $1.49Exp: 2027-10-05→ Common Stock (4,630 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2021-03-01−2,314→ 39,352 totalExercise: $1.57Exp: 2028-07-19→ Common Stock (2,314 underlying)
Footnotes (3)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 14, 2020.
- [F2]1/4 of the shares subject to the stock option vested and became exercisable on April 3, 2018, and the remaining shares vest in 36 equal monthly installments thereafter.
- [F3]1/4 of the shares subject to the stock option vested and became exercisable on July 19, 2019, and the remaining shares vest in 36 equal monthly installments thereafter.
Documents
Issuer
Vir Biotechnology, Inc.
CIK 0001706431
Entity typeother
Related Parties
1- filerCIK 0001786372
Filing Metadata
- Form type
- 4
- Filed
- Mar 2, 7:00 PM ET
- Accepted
- Mar 3, 4:35 PM ET
- Size
- 12.7 KB